1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting

MARKN.

SynAct Pharma’s Nomination Committee for the 2024 Annual General Meeting was announced in a press release on November 22, 2023. As a result of the appointment of new Board members, following a resolution by the Extra General Meeting on March 20, 2024, the composition of the Nomination Committee has changed. Henrik Stage replaces Anders Kronborg as representative for Goodwind Holding GmbH. Anders Kronborg will remain on the Nomination Committee in his capacity as Chairman of the Board of SynAct Pharma, replacing the previous Chairman of the Board in the Nomination Committee.

The Nomination Committee for the 2024 Annual General Meeting will thereafter consists of the following members:

  • Niels Ankerstjerne Sloth, Chairman of the Nomination Committee, appointed by Bioinvest Aps
  • Per Colleen, appointed by TomEnterprise Public Capital AB
  • Henrik Stage, appointed by Goodwind Holding GmbH
  • Anders Kronborg, Chairman of the Board of Directors

The Nomination Committee’s proposed items will be presented in the notice convening the Annual General Meeting and on SynAct’s web site. SynAct Pharma's Annual General Meeting 2024 will be held on Friday, May 31, 2024.

For further information, please contact:
Björn Westberg
CFO, SynAct Pharma AB 
Phone: +46 73 394 09 53 
Mail: bwe@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com. 

Attachments
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting

Datum 2024-04-23, kl 18:00
Källa MFN
Bifogade filer
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet